Stem-cell transplant for systemic sclerosis: benefit held at 10 years

A decade of follow-up on patients given an autologous stem-cell transplant for severe systemic sclerosis found that most remained free of disease progression, and that a substantial minority held remission without any ongoing immune-suppressing treatment [s1]. The study, published in The Lancet Rheumatology, is a long-term extension of a prospective European registry and offers some of the longest real-world data yet on a demanding procedure used in one of the deadliest rheumatic diseases [s1].

Why this matters

Systemic sclerosis is a rare, heterogeneous autoimmune disease that scars the skin and internal organs, and it carries the highest mortality of the rheumatic diseases with few treatment options [s1]. Autologous haematopoietic stem-cell transplantation — harvesting a patient's own blood stem cells, wiping out the misfiring immune system with chemotherapy, then rebuilding it — is already an established option for selected people with early, severe, progressing disease. What has been missing is reliable evidence on whether its benefit lasts, and at what long-term cost [s1].

What the study did

The analysis, named NISSC1-LTE, followed patients from the European Society for Blood and Marrow Transplantation's prospective NISSC1 study who had undergone their first transplant for severe progressive disease [s1]. Thirteen centres across France, Germany, the Netherlands, Italy, Spain, Switzerland and Brazil completed a yearly report for each patient still alive after two years, out to 10 years [s1]. The primary endpoint was progression-free survival — survival without evidence of the disease advancing — and the researchers also tracked late complications including cancers, new autoimmune diseases, infections and major cardiovascular events [s1]. People with lived experience of systemic sclerosis helped design and run the study, which is registered as NCT02516124 and is complete [s1].

All 80 patients transplanted between Dec 4, 2012, and Jan 19, 2016, were included [s1]. Twelve were lost to follow-up, five of them with less than five years of data [s1]. The median age at transplant was 43 years (IQR 33–51); 57 (71%) of the 80 were female and 23 (29%) male; and the median follow-up reached 9·2 years (IQR 8·9–9·6) [s1].

What it found

Progression-free survival was 81% (95% CI 71–88) at two years, 72% (61–81) at five years and 60% (47–71) at 10 years [s1]. In other words, roughly three in five patients were still alive and without disease progression a decade on — though the widening confidence intervals reflect how few patients remain at the longest timepoints, and caution against reading the 10-year figure too precisely.

Eighteen patients died during the study [s1]. The deaths were attributed to the transplant itself in five (6%) of the 80, to disease progression in nine (11%), to a post-transplant cancer in two (3%) and to late serious infection in two (3%) [s1]. That transplant-related mortality is the central trade-off: the procedure can halt an often-fatal disease, but it carries its own upfront risk of death that patients and clinicians must weigh.

The most striking durability signal was that 34 (43%) of the 80 patients maintained remission without any immunosuppressive treatment across the 10 years [s1] — a drug-free remission that conventional therapies for systemic sclerosis rarely deliver.

The researchers also tracked the late complications that have long worried clinicians about transplantation: new cancers, secondary autoimmune diseases, infections and major cardiovascular events [s1]. Those harms are part of why the procedure is reserved for severe, progressing disease rather than offered early or widely — the calculation only makes sense when the disease itself poses a comparable or greater threat. The two post-transplant cancer deaths and two late fatal infections among the 80 patients sit on that side of the ledger, alongside the five deaths tied directly to the transplant [s1]. Set against a disease that, left to progress, can be fatal within a few years, the cohort's decade of mostly preserved function is the case for the intervention; the quantified mortality is the case for restraint in who receives it.

What it means

This is a cohort study, not a randomised trial, so it describes outcomes in transplanted patients rather than proving superiority over continued drug therapy, and the group was a selected one with early, severe, progressing disease [s1]. An accompanying commentary argues the findings should reshape how "long-term success" in systemic sclerosis is defined, and positions these durable results as a benchmark against which newer cellular therapies — such as CAR T-cell approaches now entering the field — will have to be measured [s2]. The honest takeaway is narrow but meaningful: for carefully chosen patients with severe scleroderma, a one-time transplant can buy a decade of disease control, and for a sizeable minority, freedom from daily immune-suppressing drugs — against a real, quantified risk of treatment-related death.